

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM867638

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Innovatus Life Sciences Lending Fund I, LP		10/19/2023	Limited Partnership:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Centinel Spine, LLC		
<b>Street Address:</b>	505 park avenue, 14th floor		
<b>City:</b>	New York		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10022		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 17</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	85274726	ABO	
<b>Serial Number:</b>	90606493	ACTILIF	
<b>Serial Number:</b>	86755577	ALTOS	
<b>Serial Number:</b>	90606518	FLX	
<b>Serial Number:</b>	90606508	FORTOS-C	
<b>Serial Number:</b>	90606533	FUSE-THRU	
<b>Serial Number:</b>	90619471	INTEGRATED INTERBODY	
<b>Serial Number:</b>	87258345	MIDLINE II	
<b>Serial Number:</b>	88064543	MIDLINE II-TI	
<b>Serial Number:</b>	76696863	NO PROFILE	
<b>Serial Number:</b>	85412853	STALIF	
<b>Serial Number:</b>	77335083	STALIF C	
<b>Serial Number:</b>	88064531	STALIF C FLX	
<b>Serial Number:</b>	88064523	STALIF C-TI	
<b>Serial Number:</b>	88064515	STALIF L	
<b>Serial Number:</b>	77874913	STALIF MIDLINE	
<b>Serial Number:</b>	90634406	TI-ACTIVE	
<b>CORRESPONDENCE DATA</b>			

OP \$440.00 85274726

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 9494003041  
**Email:** ncuetara@gmail.com  
**Correspondent Name:** F Nicolas Cuetara  
**Address Line 1:** 8200 nw 27th street, 104  
**Address Line 4:** Doral, FLORIDA 33122

<b>NAME OF SUBMITTER:</b>	F Nicolas Cuetara
<b>SIGNATURE:</b>	/F. Nicolas Cuetara/
<b>DATE SIGNED:</b>	01/11/2024

**Total Attachments: 5**

source=Release of Security Interest Innovatus#page1.tif  
source=Release of Security Interest Innovatus#page2.tif  
source=Release of Security Interest Innovatus#page3.tif  
source=Release of Security Interest Innovatus#page4.tif  
source=Release of Security Interest Innovatus#page5.tif

# RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

This RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST ("**Release**") is made and effective as of 10/19/23 and granted by INNOVATUS LIFE SCIENCES LENDING FUND I, LP, together with its successors and assigns (the "**Collateral Agent**"), a Delaware limited partnership, as collateral agent for the secured parties under the Loan Agreement referred to below (the "**Secured Parties**"), in favor of CENTINEL SPINE, LLC, a Delaware limited liability company (the "**Grantor**") and its successors, assigns and legal representatives.

WHEREAS, pursuant to that certain Loan and Security Agreement dated as of 3/8/2021 (the "**Loan Agreement**") among the Grantor, the Collateral Agent and the lenders party thereto, the Grantor executed and delivered to the Collateral Agent that certain Intellectual Property Security Agreement by and between the Grantor and the Collateral Agent dated as of 3/8/2021 (the "**Security Agreement**");

WHEREAS, pursuant to the Security Agreement, the Grantor pledged and granted to the Collateral Agent for the ratable benefit of the Secured Parties a security interest in and to all of the right, title and interest of such Grantor in, to and under the patents and trademarks described in Schedules 1 and 2 attached hereto (the "**Released Property**");

WHEREAS, the Security Agreement was recorded with the United States Patent and Trademark Office at Reel 007215, Frame 0363 and Reel 055533, Frame 0519 on 3/9/2021; and

WHEREAS, the Grantor has requested that the Collateral Agent enter into this Release in order to effectuate, evidence and record the release and reassignment to the Grantor of any and all right, title and interest the Collateral Agent and the Secured Parties may have in the Released Property pursuant to the Security Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Collateral Agent hereby states as follows:

1. Release of Security Interest. Collateral Agent, on behalf of itself and the Secured Parties, their successors, legal representatives and assigns, hereby fully releases and terminates its security interest in the Released Property and to the extent appropriate only to further evidence its release, reassigns to Grantor, with no representation or warranty, all of the Released Property. This is a partial release, and it shall in no manner release, affect or impair the security interests in favor of Collateral Agent, under the Security Agreement or otherwise, against any Intellectual Property Collateral (as defined in the Security Agreement), other than the Released Property.

2. Further Assurances. Collateral Agent agrees, to take all further actions, at Grantor's expense, and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as the Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.

**IN WITNESS WHEREOF**, Collateral Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

INNOVATUS LIFE SCIENCES LENDING  
FUND I, LP as Collateral Agent

By: Innovatus Life Sciences GP, LP

Its: General Partner

By:  **ANDREW DYM**  
A841B97B781A48E

Name: ANDREW DYM

Title: Authorized Signatory

Address for Notices:

INNOVATUS LIFE SCIENCES LENDING  
FUND I, LP

777 Third Avenue, 25th Floor New York, NY  
10017

Attn: Claes Ekstrom

Email: cekstrom@innovatuscp.com

## SCHEDULE 1

### PATENTS

Territory	Application No.	Publication No.	Filing Date	Patent No.
United States	61/259,391	n/a	11/09/2009	n/a
United States	12/941,289	2011/0166658	11/08/2010	9,066,815
United States	14/754,919	2015/0305883	6/30/2015	9,468,534
United States	15/296,429	2017/0035574	10/18/2016	10,130,491
PCT	PCT/US2010/055825	WO 2011/057187	11/08/2010	n/a
United States	61/259,471	n/a	11/09/2009	n/a
United States	12/941,190	2011/0166656	11/08/2010	8,870,961
United States	14/524,924	2016/0113782 and 2017/0246009 A9	10/27/2014	9,918,850
PCT	PCT/US2010/055822	WO 2011/057185	11/08/2010	n/a
Australia	2010314958	2010314958	11/08/2010	2010314958
Europe -- validated in DE, ES, FR, GB, IT	10779385.3	2498720	11/08/2010	2498720
Europe -- validated in DE, ES, FR, GB, IT	16161675.0	3090706	11/08/2010	3090706
United States	61/259,401	n/a	11/08/2009	n/a
United States	12/841,393	2011/0166657	11/08/2010	8,894,708
United States	14/551,858	2015/0081027	11/24/2014	9,233,010
United States	14/870,437	2016/0015528	9/30/2015	10,206,786
PCT	PCT/US2010/055811	WO 2011/057181	11/08/2010	n/a
Australia	2010314954	2010314954	11/08/2010	2010314954
Europe -- validated in DE, ES, FR, GB, IT	10829223.6	2498723	11/08/2010	2498723
United States	61/259,605	n/a	11/09/2009	n/a
United States	12/941,213	2011/0190825	11/08/2010	9,078,701
United States	14/798,352	2016/0086039	7/13/2015	9,592,081
United States	11/938,476	2008/0185293	11/12/2007	8,728,165
United States	18/082,031	2023/0121518	12/15/2022	
United States	16/742,103	2020/0146837	1/14/2020	11,529,243
Great Britain	0721478.6	2454229	11/01/2007	2454229
United States	60/798,895	n/a	5/09/2006	n/a
United States	11/746,329	2007/0285626	5/09/2007	8,529,626
United States	61/793,847	n/a	3/15/2013	n/a
United States	14/215,718	2014/0288655	3/17/2014	8,566,166
United States	15/428,601	2017/0239061	2/09/2017	10,413,426
PCT	PCT/US2014/030251	WO 2014/145478	3/17/2014	n/a
Australia	2014232963	2014232963	3/17/2014	2014232963
Europe -- validated in CH, FR, DE, ES, UK	14763223.8	2967812	3/17/2014	2967812
Europe	21161579.4	3906898	3/09/2021	
United States	62/145,161	n/a	4/09/2015	n/a
United States	15/094,868	2016/0296343	4/08/2016	10,624,757

United States	18/073,753	TBD	12/02/2022	
United States	16/851,710	2020/0261242	4/17/2020	11,517,445
PCT	PCT/US2016/026806	WO 2016/164837	4/08/2016	n/a
Australia	2016246067	2016246067	4/08/2016	2016246067
Australia	2021201282	2021201282	2/26/2021	2021201282
Europe - validated in CH, FR, DE, ES, GB, IT	16777435.5	3280361	4/08/2016	3280361
United States	62/575,071	n/a	10/30/2017	n/a
United States	16/165,934	2019/0117410	10/19/2018	
PCT	PCT/US2018/056782	WO 2019/079768	10/19/2018	n/a
Australia	2018351068	2018351068	10/19/2018	
Canada	3,079,608	3,079,608	10/19/2018	
Europe	18867971.6	3697329	10/19/2018	
United States	15/294,530	2018/0103989	10/14/2016	10,016,224
United States	16/029,856	2018/0310966	7/9/2018	10,492,836

**SCHEDULE 2**  
**TRADEMARKS**

Territory	Mark	Serial No.	Registration No.
United States	ABO	85/274,726	4,044,714
United States	ACTILIF	90/606,493	7,049,695
United States	ALTOS	86/755,577	5,142,671
United States	FLX	90/606,518	
United States	FORTOS-C	90/606,508	7,146,152
United States	FUSE-THRU	90/606,533	6,896,415
United States	INTEGRATED INTERBODY	90/619,471	
United States	MIDLINE II	87/258,345	5,342,887
United States	MIDLINE II-TI	88/064,543	5,823,588
United States	NO PROFILE	76/696,863	3,868,807
European Union	STALIF		002419257
United Kingdom	STALIF		902419257
United States	STALIF	85/412,853	4,170,623
United States	STALIFC	77/335,083	3,680,564
United States	STALIFC FLX	88/064,531	5,725,944
United States	STALIFC-TI	88/064,523	5,725,943
United States	STALIFL	88/064,515	5,725,942
European Union	STALIFMIDLINE		008661746
United Kingdom	STALIFMIDLINE		908661746
United States	STALIFMIDLINE	77/874,913	4,003,160
United States	TI-ACTIVE	90/634,406	